Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fuente, Adolfo de La
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Recruiting	3	550	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	02/29
NCT05022797: Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS	Terminated	2	3	Europe	Glucarpidase 1000 UNT [Voraxaze], VORAXAZE®, P21011D	Fundacion CRIS de Investigación para Vencer el Cáncer, BioClever 2005 S.L., Eurofins ADME, S.L., NTShub, S.L., BTG International Inc.	Diffuse Large B-Cell Lymphoma, Drug Toxicity	11/22	11/22
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML	Recruiting	2	98	Europe	RVU120, SEL120, Venetoclax	Ryvu Therapeutics SA	Acute Myeloid Leukemia	02/26	09/26
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia	Active, not recruiting	1/2	218	Europe, US	Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto	ImmunoGen, Inc., Jazz Pharmaceuticals	Acute Myeloid Leukemia	12/24	12/24